Half-year report · Q2
2784.TEDINET S100UPC8
Period2024-04-01 → 2024-09-30
Filed2024-11-12
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.46T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥2.86T | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.43T | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥16.0bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥16.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥40.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.3bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥20.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.4bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.6bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥11.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.47T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.45T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.43T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥975.8bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥967.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥491.3bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥479.9bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥465.6bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥206.8bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥213.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥204.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥212.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥184.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥158.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥86.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥63.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥8.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥14.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥7.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥19.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥29.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥75.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥154.13 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.29 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 33.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥174m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.30T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.29T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥27.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.9bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.1bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥188m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥248m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥132.4bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥132.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥258m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.46T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥18.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥14.8bn |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | ¥269m |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.27T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.26T |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥8.9bn |
| jpcrp040300-q2r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥13.8bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥26.0bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.3bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7.7bn |
| jpcrp040300-q2r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥186m |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥18.2bn |
| jpcrp040300-q2r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥279m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥133.3bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥133.1bn |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥275m |
| jpcrp040300-q2r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥1.44T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥1.43T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥16.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥15.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 562
| Item | Context | Value | Unit |
|---|---|---|---|
| Raw materials and supplies | CurrentQuarterInstant | 7633000000 | JPY |
| Other ca | Prior1YearInstant | 105320000000 | JPY |
| Other ca | CurrentQuarterInstant | 101410000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -335000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -342000000 | JPY |
| Current assets | Prior1YearInstant | 1121233000000 | JPY |
| Current assets | CurrentQuarterInstant | 1125071000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 79081000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 77468000000 | JPY |
| Land | Prior1YearInstant | 72239000000 | JPY |
| Land | CurrentQuarterInstant | 71139000000 | JPY |
| Other net ppe | Prior1YearInstant | 30280000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 34737000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 181601000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 183345000000 | JPY |
| Goodwill | Prior1YearInstant | 2065000000 | JPY |
| Goodwill | CurrentQuarterInstant | 1815000000 | JPY |
| Other ia | Prior1YearInstant | 14507000000 | JPY |
| Other ia | CurrentQuarterInstant | 14501000000 | JPY |
| Intangible assets | Prior1YearInstant | 16572000000 | JPY |
| Intangible assets | CurrentQuarterInstant | 16317000000 | JPY |
| Investment securities | Prior1YearInstant | 105627000000 | JPY |
| Investment securities | CurrentQuarterInstant | 115586000000 | JPY |
| Other ioa | Prior1YearInstant | 25989000000 | JPY |
| Other ioa | CurrentQuarterInstant | 29217000000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -3398000000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -2391000000 | JPY |
| Investments and other assets | Prior1YearInstant | 128218000000 | JPY |
| Investments and other assets | CurrentQuarterInstant | 142412000000 | JPY |
| Noncurrent assets | Prior1YearInstant | 326392000000 | JPY |
| Noncurrent assets | CurrentQuarterInstant | 342075000000 | JPY |
| Assets | Prior1YearInstant | 1447625000000 | JPY |
| Assets | CurrentQuarterInstant | 1467147000000 | JPY |
| Notes and accounts payable trade | Prior1YearInstant | 855328000000 | JPY |
| Notes and accounts payable trade | CurrentQuarterInstant | 861863000000 | JPY |
| Income taxes payable | Prior1YearInstant | 7961000000 | JPY |
| Income taxes payable | CurrentQuarterInstant | 11111000000 | JPY |
| Provision for bonuses | Prior1YearInstant | 8028000000 | JPY |
| Provision for bonuses | CurrentQuarterInstant | 7177000000 | JPY |
| Provision for directors bonuses | Prior1YearInstant | 439000000 | JPY |
| Provision for directors bonuses | CurrentQuarterInstant | 179000000 | JPY |
| Provision for share based remuneration cl | Prior1YearInstant | － | JPY |
| Provision for share based remuneration cl | CurrentQuarterInstant | 218000000 | JPY |
| Provision for share based remuneration for directors and other officers cl | Prior1YearInstant | － | JPY |
| Provision for share based remuneration for directors and other officers cl | CurrentQuarterInstant | 239000000 | JPY |
| Provision for loss on anti monopoly act cl | Prior1YearInstant | 4937000000 | JPY |
| Provision for loss on anti monopoly act cl | CurrentQuarterInstant | 4937000000 | JPY |
| Other cl | Prior1YearInstant | 30293000000 | JPY |
| Other cl | CurrentQuarterInstant | 27884000000 | JPY |
| Current liabilities | Prior1YearInstant | 906989000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |